Isoprenaline Hydrochloride Synchrony Pharma (Isoprenaline Hydrochloride)

The drug acts as a non‑selective beta‑adrenergic agonist, binding to β1 receptors in the heart and β2 receptors in the lungs. Activation of these receptors increases cyclic AMP levels, which enhances cardiac contractility and rate while causing bronchodilation through smooth‑muscle relaxation.

The specific dose of Isoprenaline Hydrochloride is determined by the prescribing clinician based on the patient’s condition, weight, age, and response. Healthcare professionals adjust the intravenous infusion rate to achieve the desired therapeutic effect while monitoring vital signs.

Safety data for Isoprenaline Hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with selective β1‑agonists such as dobutamine, Isoprenaline Hydrochloride stimulates both β1 and β2 receptors, producing a stronger increase in heart rate and more pronounced bronchodilation. This broader activity can be advantageous in combined cardiac‑respiratory emergencies but may also raise the risk of side effects like tachyarrhythmias.

Isoprenaline Hydrochloride should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain its stability and potency.

The medication is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, who sets the infusion rate according to the patient’s clinical response and continuously monitors cardiac and respiratory parameters.

The most critical risks include life‑threatening arrhythmias, myocardial ischemia, severe hypertension or hypotension, pulmonary edema, and anaphylactic reactions. Prompt recognition and immediate medical intervention are essential if any of these serious adverse events occur.

Isoprenaline Hydrochloride is contraindicated in patients with pheochromocytoma, uncontrolled hypertension, severe coronary artery disease, or known hypersensitivity to the drug. It should also be used with extreme caution in individuals with recent myocardial infarction or significant electrolyte disturbances.